Hanmi Pharm (KRX:128940) posted first-quarter net income attributable to shareholders of the parent company of 42.6 billion won, down 22.5% from 55 billion won a year earlier, the pharmaceutical company said in a Tuesday regulatory filing with Korea Exchange.
The company's sales fell 3.2% year over year to 390.9 billion won from 403.7 billion won.
Shares of Hanmi Pharm jumped nearly 9% at market close on Wednesday, April 30.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。